IFNG and neoplasm: The combination of FA‐CS/mIP‐10 NMs and DC/anti‐LC fusion vaccines significantly reduced the MDSCs in the spleen, local tumors, and bone marrow of mice, while increasing tumor‐specific IFN‐γ responses, thereby enhancing the therapeutic efficacy of the original fusion vaccine and alleviating the immunosuppressive TME.[206] In addition, the therapeutic effect on LC can be enhanced by designing combination drug delivery systems conjugated with FA.